The emerging role of systemic inflammation in chronic obstructive pulmonary disease

Clinical Pulmonary Medicine

Volumn 15, Issue 2, 2008, Pages 55-62

  Tran, Betty ^a   Kalhan, Ravi ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

C reactive protein; Chronic obstructive pulmonary disease; Fibrinogen; Systemic inflammation

Indexed keywords

BUDESONIDE; C REACTIVE PROTEIN; CORTICOSTEROID DERIVATIVE; EPIDERMAL GROWTH FACTOR; FIBRINOGEN; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO; PREDNISONE; SALMETEROL; THROMBOXANE A2; TRANSFORMING GROWTH FACTOR BETA; TRIAMCINOLONE; TUMOR NECROSIS FACTOR ALPHA;

AIR POLLUTION; BODY MASS; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; HEREDITY; HUMAN; HYPERINFLATION; HYPOXEMIA; INFLAMMATION; LUNG FUNCTION; META ANALYSIS; MORBIDITY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PARTICULATE MATTER; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW;

EID: 40949138476     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/CPM.0b013e3181671a46     Document Type: Review

References (56)

1. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27:397-412.
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349:1498-1504.
3. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645-2653.
4. John M, Hoernig S, Doehner W, et al. Anemia and inflammation in COPD. Chest. 2005;127:825-829.
5. Creutzberg EC, Casaburi R. Endocrinological disturbances in chronic obstructive pulmonary disease. Eur Respir J Suppl. 2003;46:76s-80s.
6. Laghi F, Antonescu-Turcu A, Collins E, et al. Hypogonadism in men with chronic obstructive pulmonary disease: prevalence and quality of life. Am J Respir Crit Care Med. 2005;171:728-733.
7. Agusti AG, Sauleda J, Miralles C, et al. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166:485-489.
8. Schols AM, Slangen J, Volovics L, et al. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1791-1797.
9. Balasubramanian VP, Varkey B. Chronic obstructive pulmonary disease: effects beyond the lungs. Curr Opin Pulm Med. 2006;12:106-112.
10. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16:63-70.
11. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005;127:1952-1959.
12. Hole DJ, Watt GC, Davey-Smith G, et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ. 1996;313:711-716.
13. Schunemann HJ, Dorn J, Grant BJ, et al. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest. 2000;118:656-664.
14. Marcus EB, Curb JD, MacLean CJ, et al. Pulmonary function as a predictor of coronary heart disease. Am J Epidemiol. 1989;129:97-104.
15. Lange P, Nyboe J, Jensen G, et al. Ventilatory function impairment and risk of cardiovascular death and of fatal or non-fatal myocardial infarction. Eur Respir J. 1991;4:1080 -1087.
16. Hospers JJ, Rijcken B, Schouten JP, et al. Eosinophilia and positive skin tests predict cardiovascular mortality in a general population sample followed for 30 years. Am J Epidemiol. 1999;150:482-491.
17. Kuller LH, Ockene JK, Townsend M, et al. The epidemiology of pulmonary function and COPD mortality in the multiple risk factor intervention trial. Am Rev Respir Dis. 1989;140:S76-S81.
18. Speizer FE, Fay ME, Dockery DW, et al. Chronic obstructive pulmonary disease mortality in six US. cities. Am Rev Respir Dis. 1989;140:S49-S55.
19. Hozawa A, Billings JL, Shahar E, et al. Lung function and ischemic stroke incidence: the Atherosclerosis Risk in Communities study. Chest. 2006;130:1642-1649.
20. Roberts HR, Monroe DM, Hoffman M. Molecular biology and biochemistry of the coagulation factors and pathways of hemostasis. In: Lichtman MA, Beutler E, Kipps TJ, et al. eds. Williams Hematology. New York, NY: McGraw-Hill; 2006.
21. Dahl M, Tybjaerg-Hansen A, Vestbo J, et al. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:1008-1011.
22. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med. 2003;114:758-762.
23. Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005;128:1995-2004.
24. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59:574-580.
25. Thyagarajan B, Jacobs DR, Apostol GG, et al. Plasma fibrinogen and lung function: the CARDIA Study. Int J Epidemiol. 2006;35:1001-1008.
26. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-454.
27. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
28. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
29. Dahl M, Vestbo J, Lange P, et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:250-255.
30. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107:1514-1519.
31. Pinto-Plata VM, Livnat G, Girish M, et al. Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD. Chest. 2007;131:37-43.
32. Aronson D, Roterman I, Yigla M, et al. Inverse association between pulmonary function and C-reactive protein in apparently healthy subjects. Am J Respir Crit Care Med. 2006;174:626-632.
33. Fogarty AW, Britton JR, Jones S, et al. A prospective study of systemic inflammation and decline in lung function in a general population. Thorax. 2007;62:515-520.
34. Shaaban R, Kony S, Driss F, et al. Change in C-reactive protein levels and FEV1 decline: a longitudinal population-based study. Respir Med. 2006;100:2112-2120.
35. Man SF, Connett JE, Anthonisen NR, et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax. 2006;61:849-853.
36. Chung KF. Inflammatory mediators in chronic obstructive pulmonary disease. Curr Drug Targets Inflamm Allergy. 2005;4:619-625.
37. Rolin S, Masereel B, Dogne JM. Prostanoids as pharmacological targets in COPD and asthma. Eur J Pharmacol. 2006;533:89-100.
38. Pratico D, Basili S, Vieri M, et al. Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2alpha-III, an index of oxidant stress. Am J Respir Crit Care Med. 1998;158:1709 -1714.
39. Tapson VF. The role of smoking in coagulation and thromboembolism in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005; 2:71-77.
40. Davi G, Basili S, Vieri M, et al. Enhanced thromboxane biosynthesis in patients with chronic obstructive pulmonary disease. The Chronic Obstructive Bronchitis and Haemostasis Study Group. Am J Respir Crit Care Med. 1997;156:1794-1799.
41. Ashitani J, Mukae H, Arimura Y, et al. Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease. Intern Med. 2002;41:181-185.
42. Sin DD, Lacy P, York E, et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170:760-765.
43. Barnes NC, Qiu YS, Pavord ID, et al. Anti-inflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med. 2006;173:736-743.
44. Sutherland ER, Allmers H, Ayas NT, et al. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax. 2003;58:937-941.
45. Sin DD. Inhaled corticosteroids and mortality in COPD. Thorax. 2006;61:918.
46. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775-789.
47. MacNee W. Oxidants and COPD. Curr Drug Targets Inflamm Allergy. 2005;4:627-641.
48. Alfaro-Moreno E, Nawrot TS, Nemmar A, et al. Particulate matter in the environment: pulmonary and cardiovascular effects. Curr Opin Pulm Med. 2007;13:98-106.
49. van Eeden SF, Tan WC, Suwa T, et al. Cytokines involved in the systemic inflammatory response induced by exposure to particulate matter air pollutants (PM(10)). Am J Respir Crit Care Med. 2001;164:826-830.
50. Miller KA, Siscovick DS, Sheppard L, et al. Long-term exposure to air pollution and incidence of cardiovascular events in women. N Engl J Med. 2007;356:447-458.
51. Pedersen BK, Hoffman-Goetz L. Exercise and the immune system: regulation, integration, and adaptation. Physiol Rev. 2000;80:1055-1081.
52. Vassilakopoulos T, Roussos C, Zakynthinos S. The immune response to resistive breathing. Eur Respir J. 2004;24:1033-1043.
53. Reid MB. Invited Review: Redox modulation of skeletal muscle contraction: what we know and what we don't. J Appl Physiol. 2001;90:724-731.
54. Takabatake N, Nakamura H, Abe S, et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1179-1184.
55. Pankow JS, Folsom AR, Cushman M, et al. Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis. 2001;154:681-689.
56. Brull DJ, Serrano N, Zito F, et al. Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol. 2003;23:2063-2069.